Navigation Links
ANX in Medical News

ADVENTRX Pharmaceuticals Announces Closing of Financing

... SAN DIEGO, July 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has completed the previously announced sale of shares of its 5% Series B convertible preferred stock pursuant to a registere...

ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea

...h 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has granted Shin Poong Pharmaceutical Co., Ltd. (...ted Mr. Byung Hwa Kim, Chief Executive Officer of Shin Poong. About anx -514 (docetaxel emulsion) ANX-514 is a novel nano-emulsion formulation ...

ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results

... simultaneous webcast at http://www.adventrx.com SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that it will host a conference call with simultaneous webcast to discuss third quarter 2008 results on Thursday, November 6th, 2008 ...

ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update

... simultaneous webcast at http://www.adventrx.com SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of c...

ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results

...fic); simultaneous webcast at http://www.adventrx.com SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on Monday, May 12th, 2008 at 1:3...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...uker Corporation (Nasdaq: BRKR ) Halozyme Therapeutic (Nasdaq: HALO ) Emerging Cancer Index (HHJ) Drop Adventrx Pharmaceuticals, Inc. (Amex: anx ) Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) Add Dyanvax Technologies (Nasdaq: DVAX ) Synta Pharmaceuticals Corp. (Nasdaq: SNTA ) Enab...

ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference

... SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference

... SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference

... SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference

... SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

More>>

ANX in Medical Technology

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

... Updates guidance regarding strategic transaction process SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced results from its bioequivalence study of ANX-514 (docetaxel emulsion). ANX-514 was determined to have comparable overall safety as ...

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)

... SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based b...

ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results

... SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic col...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

... SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFacto...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

...e American Society of Clinical Oncology SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general disor...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

...esents Results at Keystone Symposia HIV Pathogenesis Conference SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV P...

ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

... SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer...

ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference

... SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for pres...

ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer

... SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study

... SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the prim...
ANX in Biological Technology

ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12

... SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced that it will hold a conference call on Wednesday, August 12, 2009 at 1:30 p.m. Pacific (4:30 p.m. Eastern) to review financial resul...

ADVENTRX Pharmaceuticals Announces Financing

... SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a si...

ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009

...nal manufacturing activities for ANX-530 NDA re-started SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced its plans for the remainder of 2009. Following the financing that closed earlier this month, ADVENTRX has re-started the fina...

ADVENTRX Pharmaceuticals Announces Closing of Financing

... SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced that it has completed the previously announced sale of shares of convertible preferred stock pursuant to a registered direct offerin...

ADVENTRX Pharmaceuticals Announces Financing

... SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a si...

ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results

... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today reported financial results for the fourth quarter and year ended December 31, 2008. "2008 was a transition year for ADVENTRX in which we ...

ADVENTRX Announces Further Cost-Cutting Measures

... SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that, effective April 3, it will reduce its full-time workforce to five employees and will discontinue substantially all of its deve...

ADVENTRX Exploring Strategic Options

..., Dec. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and comm...velopment and commercialization of its lead product candidates, ANX-530 and anx 514; the risk that ADVENTRX's stockholders will not approve a transaction r...

ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update

...GO, Nov. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and comm...uding funding the continued development and commercialization of ANX-530 or anx 514; the risk that restructuring costs may be greater than anticipated and ...

ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference

... SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that Mark Erwin, Senior Vice President, Operations of ADVENTRX, is scheduled to present at the Rodman & Renshaw 10th Annual Global H...
Other Tags
(Date:8/27/2015)... ... 2015 , ... In an article published July 30th by the ... New Orleans, highlighting a security firm that is tasked with providing supplemental protection. Called ... who worked with the city to provide private security when it is needed in ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), part ... medical centers in the United States to receive international recognition for an advanced, ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions dedicated ...
(Date:8/27/2015)... Michigan (PRWEB) , ... August 27, 2015 , ... On ... returned for the second year as sponsor of the “Music With A Mission” benefit ... raise money for music education programs in the underfunded school districts of Mendon and ...
(Date:8/27/2015)... ... 27, 2015 , ... Dr. Jennifer Arnold, co-star of “The Little Couple” and ... 3rd Annual MPN Heroes™ recognition event on Friday, Dec. 4, prior to ... honoring eight heroes who have made significant contributions in the field of rare blood ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is ... October 27-29, 2015 in San Jose, CA. The first event dedicated to ... the void that exists where battery development and energy storage innovation are concerned. ...
Breaking Medicine News(10 mins):Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
Other Contents